Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Human-Centric Modeling in Metastatic Breast Cancer: Organoids, Organ-on-Chip Systems, and New Approach Methodologies in the Post-FDA Modernization Act 2.0 Era.Cancers · 2026
   Review
2. Comparative analysis of 3D-culture techniques for multicellular colorectal tumour spheroids and development of a novel SW48 3D-model.Scientific reports · 2025
   Article
3. Bone Marrow Adipocytes Contribute to Tumor Microenvironment-Driven Chemoresistance via Sequestration of Doxorubicin.Cancers · 2023
   Article

Corrections and comments

• Erratum for
  Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.2015

Authors and funding

15 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.